CEL-SCI Corporation

465 articles with CEL-SCI Corporation

• U.S. Patent Office Allows New CEL-SCI Patents for LEAPS Vaccine Platform Technology

  6/8/2018

  New LEAPS Patents aimed at Multiple Infectious Diseases

• CEL-SCI to Present Today at the 8th Annual LD Micro Invitational

  6/5/2018

  CEL-SCI Corporation announced that Geert Kersten, Chief Executive Officer, will be presenting today, June 5, 2018 at 12:00 pm PT / 3:00 pm ET at the 8th annual LD Micro Invitational.

• CEL-SCI Announces Reminder of Warrant Exercise Price

  5/30/2018

  CEL-SCI Corporation wants to remind its shareholders that the lower exercise price for its outstanding Series S warrants.

• CEL-SCI Corporation Announces Upcoming Investor Conference Presentations

  5/2/2018

  CEL-SCI Corporation announces that Geert Kersten, Chief Executive Officer, will present at upcoming conferences.

• CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results

  2/13/2018

  CEL-SCI reported an operating loss of ($4,911,430) for the quarter ended December 31, 2017 versus an operating loss of ($4,938,008) for the quarter ended December 31, 2016.

• CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Conference

  2/12/2018

  CEL-SCI announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.m.

• CEL-SCI to Present at 2018 BIO CEO & Investor Conference

  2/5/2018

  CEL-SCI announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.m.

• U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology

  1/30/2018

  CEL-SCI’s patented invention relates to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.

• CEL-SCI Announces Adjustment to Warrant Exercise Price

  1/16/2018

  CEL-SCI announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 per share of common stock for a three month period which will end on April 12, 2018.

• CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis

  1/8/2018

  CEL-SCI Corporation today announced that the European Patent Office has issued CEL-SCI patent EP 2254588B1 titled, “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS™(*) platform technology.

• CEL-SCI Issues Letter to Shareholders

  1/3/2018

  CEL-SCI enters 2018 in a position of strength and hope for the year ahead.

• CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments

  1/2/2018

  CEL-SCI reported a net loss of ($14.36) million in fiscal year 2017 versus a net loss of ($11.51) million in fiscal 2016.

• CEL-SCI Announces Robert Watson Joins Its Board of Directors

  12/18/2017

  Mr. Watson has over 35 years of experience in the healthcare IT industry as a CEO, board member and advisor to multiple companies.

• CEL-SCI Reaches Full Enrollment in Pivotal Phase III Head and Neck Cancer Study

  12/12/2017

  The primary endpoint of the study, a 10% improvement in overall survival of the Multikine treatment regimen plus Standard of Care (SOC) vs. Standard of Care alone, will be determined after a total of 298 deaths have occurred in these two main comparator arms of the study and have been recorded in the study database.

• CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase III Head and Neck Cancer Study

  12/7/2017

  CEL-SCI Corporation announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its review of the Phase 3 study data.

• CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016 - Nov. 28, 2017

  11/28/2017

  Following the Company’s reverse split in June 2017, twenty-five (25) Series DD and Series EE warrants will be required to purchase one share at an exercise price of $4.50.

• CEL-SCI Announces Update on Arbitration Against Former Clinical Research Organization

  11/13/2017

  The last witness in the arbitration hearing testified on Wednesday, November 8, 2017, and no further witnesses or testimony are expected.

• CEL-SCI Granted European Patent For Multikine's Mechanism Of Action In Making Tumors "Visible" To The Immune System

  10/10/2017

• CEL-SCI Announces Update On Ongoing Arbitration Against Former Clinical Research Organization

  10/5/2017

• CEL-SCI Announces $1.5 Million NIH SBIR Grant To Support Development Of Rheumatoid Arthritis Vaccine

  9/19/2017